To use this feature, join Babbler easily !
Babbler allows PR people and reporters to collaborate a better way.
By joining Babbler you will be able to access hundreds of newsrooms and PR contacts from your industrie(s) and also share with them your upcoming needs.
Their newsrooms are already on Babbler
You're 1 click away from signing up
Nice to see you again !
Ethypharm appoints Frédéric MOLIN to leads its Corporate Development
minutes reading time
minute reading time
St Cloud, France – 19th june 2018 – Ethypharm is pleased to welcome Frédéric MOLIN to Ethypharm Group as Executive Vice President Corporate Development.
Frédéric MOLIN will be responsible to initiate and lead strategic development programs encompassing in-licensing, partnerships and M&A.
Frédéric is a Pharmacist and holds a Master’s Degree in Strategy and Marketing. He brings a wealth of experience and expertise in Business Development and in-Licensing.
Frédéric will report directly to Hugues Lecat - Chief Executive Officer - who declared: “Frédéric will bring a fresh perspective to the Group and his proven business acumen and joint pharmacist & marketing expertise will enable him to make a valuable contribution to develop our business”.
Frédéric began his career in 1996 at Laboratoires Fournier, where he gained experience in marketing studies, evaluation of in-licensing opportunities, negociation and implementation of different partnership and licensing agreements. In 2005, Frédéric moved to Laboratoires Pierre Fabre to take up the role of corporate licensing manager. In 2013, Frédéric was appointed corporate licensing acquisition Director.
Ethypharm is a European-based specialty pharmaceutical company with global reach and a committed player in the treatment of pain and addiction. Ethypharm also develops and markets complex generics and essential medicines that help reduce healthcare costs, particularly in the field of emergency care and oncology. The Company employs 1400 people mainly in Europe, and its drugs are marketed in more than 80 countries. Our ambition is to become the European leader for the treatment of pain and addiction, and to help patients around the world gain access to high quality, essential and affordable medicines.
Press contact – Avril Ponnelle/ email@example.com /+ 33 (0) 1 41 12 17 20
Congratulations, you're registered on Babbler!
Discover now all the news waiting for you on Babbler: visit your newsfeed.!
Your topics have been selected, you can change it by clicking here